RECRUITINGOBSERVATIONAL
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
About This Trial
The goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have melanoma or non-melanoma skin cancers. The main question it aims to answer is: * Are blood based signatures able to predict progression-free survival (PFS)? Participants undergoing regular treatment for their skin cancer will provide blood samples.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age ≥18 years.
- Participants must meet at least one of the following criteria:
- Finding suspicious of melanoma or non-melanoma skin cancer based on clinical, radiographic, or laboratory findings. Non-melanoma skin cancers include: basal cell carcinoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma.
- A confirmed diagnosis of melanoma or non-melanoma skin cancer.
Who Should NOT Join This Trial:
- Vulnerable populations, including pregnant women, those who lack consent capacity, the mentally ill, prisoners, cognitively impaired persons, children (age \<18), and UW employees that report to the investigator(s) or to study team members.
- Not suitable for study participation due to other reasons at the discretion of the investigators.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age ≥18 years.
* Participants must meet at least one of the following criteria:
* Finding suspicious of melanoma or non-melanoma skin cancer based on clinical, radiographic, or laboratory findings. Non-melanoma skin cancers include: basal cell carcinoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma.
* A confirmed diagnosis of melanoma or non-melanoma skin cancer.
Exclusion Criteria:
* Vulnerable populations, including pregnant women, those who lack consent capacity, the mentally ill, prisoners, cognitively impaired persons, children (age \<18), and UW employees that report to the investigator(s) or to study team members.
* Not suitable for study participation due to other reasons at the discretion of the investigators.
Treatments Being Tested
OTHER
Blood draw for the laboratory assessment
Participants will have 50 milliliters (3.5 tablespoons) of blood drawn
Locations (1)
University of Wisconsin
Madison, Wisconsin, United States